OCS Profile
Oculis Holding AG is a clinical-stage biopharmaceutical company specializing in the development of innovative topical treatments for a range of ophthalmic conditions affecting both the front and back of the eye. The company’s research and development efforts are focused on addressing unmet needs in ocular health through advanced drug delivery systems and novel therapeutic approaches. Its portfolio includes several key candidates, each targeting different aspects of ocular disease management and treatment.
The company’s leading product, OCS-01, is a topical dexamethasone formulation currently advancing through Phase 3 clinical trials. OCS-01 is designed for the treatment of diabetic macular edema (DME), a severe complication of diabetes that affects the retina and can lead to vision loss. This product represents a critical component of Oculis’s strategy to offer more effective and less invasive treatment options for chronic ocular conditions.
Another notable candidate in Oculis’s pipeline is OCS-02, a topical biologic currently undergoing Phase 2b clinical trials. This treatment is aimed at managing keratoconjunctivitis sicca, commonly known as dry eye disease. Dry eye disease affects millions of people globally, and OCS-02 seeks to provide a more targeted and effective solution to alleviate the symptoms and improve patient quality of life.
Oculis is also developing OCS-05, a novel neuroprotective agent intended for the treatment of acute optic neuritis and other neuro-ophthalmological disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The advancement of these therapies underscores the company's commitment to addressing complex ocular conditions with innovative solutions. Headquartered in Zug, Switzerland, Oculis Holding AG continues to drive forward its mission of revolutionizing ocular disease treatment and improving patient outcomes through cutting-edge research and development.
|
